Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • Eleven Minutes
    • Priced Out
    • Data Grab
    • Memory Gaps
    • Growing Up Scared
    • Denied
    • Opioid Settlement Tracking
    • Guns, Race, and Profit
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email
  • Add Us to Google

Monday, Nov 16 2026 UPDATED 8:57 AM

Full Issue

Researchers Find Possible Link Between Colon Cancer And Microplastics

Colorectal cancer rates have risen 3% annually among young adults ages 20-49, raising concern among doctors and researchers. Now, microplastics and nanoplastics are emerging as potential culprits.

The Washington Post: Microplastics Can Make People More Vulnerable To Colon Cancer 

A study released last month from researchers at Central South University in China found that long-term exposure to polystyrene nanoplastics — the plastic that is used in Styrofoam cups and take-out containers — promoted tumor growth in mice that were genetically modified to be predisposed to colon cancer for research purposes. The nanoplastics, researchers found, built up in the colon, disrupting the cells lining the gut and damaging the balance of gut bacteria. The mice exposed to nanoplastics had more tumors and more severe tumors than those that were not exposed. (Osaka, 11/15)

The New York Times: F.D.A. Rejects Closely Watched Lung Cancer Drug From China

The Food and Drug Administration rejected a first-of-its-kind cancer drug that was invented in China, a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development. Summit Therapeutics, the Florida company that has been seeking to bring the drug to the American market, disclosed the agency’s decision in a news release on Sunday. Summit bought the U.S. rights to the drug from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories and sells it in China. (Robbins, 11/15)

The New York Times: Research Stalls For A Year Into A Cancer That Kills Children In A Year

When Ryleigh Schecter answered the front door to her home, she was wearing an oversized lavender bow in her hair that matched the stripes on her shirt. “Rainbow” is her favorite color, she told me as I sat with her and her parents, Amanda and Aaron, in their cozy living room in Twinsburg, Ohio. To prove it, she recited the colors of the spectrum in order, adding “pink, silver, gold” at the end. She is 5. (Miller, 11/15)

On Alzheimer's and ALS —

MedPage Today: Alzheimer's Study Tracks Faster Tau Buildup In Younger Patients

People with early-onset Alzheimer's disease had faster and more severe accumulation of tau than those whose Alzheimer's symptoms started after age 65, imaging data showed. Compared with older Alzheimer's patients, tau burden was higher in younger patients and spread more rapidly across a wider area of the brain, reported Konstantinos Chiotis, MD, PhD, of the Karolinska Institutet in Stockholm, and co-authors. (George, 11/13)

The New York Times: Brain Implants Give A.L.S. Patients The Voice To Speak And Sing

Brain signals from a 46-year-old man who lost his voice to A.L.S. were decoded by experimental brain implants and translated directly into intelligible speech. A 58-year-old woman, a trained singer, whose voice was gradually silenced by the disease, was able to sing a musical scale. The new advances from researchers at the University of California, Davis, to be presented next week at the Society for Neuroscience conference in Washington, demonstrate that research into brain-computer interfaces are crossing from proof-of-concept demonstrations into everyday usefulness. (Johnson, 11/14)

More health and wellness news —

NBC News: Women With Autoimmune Diseases Often Misdiagnosed For 4 Years Or More

Women with autoimmune diseases such as lupus or rheumatoid arthritis are more likely to be misdiagnosed or get delayed treatment compared with men, with their symptoms often dismissed as “psychological.” An online survey by British researchers found that it took women with an autoimmune disorder about four years to get a diagnosis, while it took men around three months to less than a year. (O'Connor, 11/15)

MedPage Today: Tirzepatide Cuts BMI In Adolescents With Obesity In Phase III Trial

Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. (Monaco, 11/15)

Fox News: Salt Substitute Swap Could Cut Heart Disease And Kidney Disease Globally

Replacing regular table salt with a potassium-enriched alternative could prevent nearly three million deaths and more than 10 million cases of heart and kidney disease worldwide every year, according to a major study published in Nature Health. Researchers at the Australia-based George Institute for Global Health analyzed dietary patterns and disease risks among 4.6 billion adults across 193 countries to estimate the potential benefits of the switch. (Quill, 11/15)

The Hill: Dietary Supplement Recalled Over Undeclared ED Ingredient: FDA

A California-based company has recalled its honey dietary supplement after an undeclared ingredient used to treat erectile dysfunction was discovered in its products. Eros Apothecary said its Candy Power For Man Organic Honey product contained tadalafil, according to a notice issued by the U.S. Food and Drug Administration. “The recall was initiated after FDA laboratory testing identified undeclared tadalafil,” the notice said. (Taub, 11/13)

Stat: Versant, Lilly Put $100 Million Behind New Startup Aimed At Solving One Of Gene Therapy’s Thorniest Issues 

Versant Ventures, Eli Lilly, and a handful of other investors announced Monday that they have poured $100 million into a new startup devoted to solving a gene therapy challenge that has ensnared many well-funded academics and biotechs before it. The company, called Seawolf Therapeutics, is trying to deliver genes to patients without the use of viruses. In addition to the $100 million fundraising, Sanofi has also inked a partnership with the company. (Mast, 11/16)

Stat: Apple And OpenEvidence Launch Experimental Health Chat App 

Apple and OpenEvidence on Sunday launched a study based around an experimental artificial intelligence-powered health chat application, hinting at possible new directions for both companies. (Aguilar and Trang, 11/15)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, November 16
  • Friday, November 13
  • Thursday, November 12
  • Tuesday, November 10
  • Friday, November 6
  • Thursday, November 5
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF